Last reviewed · How we verify
Triptorelin Pamoate PR 3-month
Triptorelin Pamoate PR 3-month is a gonadotropin-releasing hormone (GnRH) agonist that works by mimicking the action of the natural hormone GnRH, leading to a decrease in sex hormone production.
Triptorelin Pamoate PR 3-month is a gonadotropin-releasing hormone (GnRH) agonist that works by mimicking the action of the natural hormone GnRH, leading to a decrease in sex hormone production. Used for Prostate cancer, Premature puberty.
At a glance
| Generic name | Triptorelin Pamoate PR 3-month |
|---|---|
| Also known as | Triptorelin pamoate for injection 15 mg |
| Sponsor | Ipsen |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This decrease in sex hormone production is achieved through continuous stimulation of the GnRH receptors in the pituitary gland, resulting in a downregulation of GnRH receptors and a decrease in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). As a result, sex hormone production is reduced, leading to a decrease in testosterone levels.
Approved indications
- Prostate cancer
- Premature puberty
Common side effects
- Hot flashes
- Injection site reaction
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis (PHASE3)
- Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |